Европска Унија - Мелтешки - EMA (European Medicines Agency)

ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - majjali - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:-           clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6-           clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins-           clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin.

Европска Унија - Мелтешки - EMA (European Medicines Agency)

ceva-phylaxia veterinary biologicals co. ltd - turkey herpes virus, strain rhvt/nd/ibd, expressing the fusion protein of newcastle disease virus and the vp2 protein of infectious bursal disease virus, live recombinant - immunoloġiċi għall-għasafar - embryonated chicken eggs; chicken - for the active immunisation of one-day-old chicks or 18-day-old chicken embryonated eggs to reduce mortality, clinical signs and lesions caused by newcastle disease virus (ndv) and to reduce virus shedding; to reduce mortality, clinical signs and bursa lesions caused by very virulent infectious bursal disease virus (ibdv); to reduce mortality, clinical signs and lesions caused by classical marek’s disease virus (mdv).

Европска Унија - Мелтешки - EMA (European Medicines Agency)

ceva-phylaxia co. ltd. - recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus, live - chicken - for active immunisation of chickens from 8 weeks of age in order to reduce the skin lesions due to fowlpox and to reduce the clinical signs and tracheal lesions due to avian infectious laryngotracheitis.

Европска Унија - Мелтешки - EMA (European Medicines Agency)

zoetis belgium sa - inactivated bluetongue virus, serotype 1, strain btv-1/alg2006/01, inactivated bluetongue virus, serotype 8, strain btv-8/bel2006/02 - bluetongue virus, sheep, inactivated viral vaccines - nagħaġ - immunizzazzjoni attiva tan-nagħaġ minn 1. 5 xhur għall-prevenzjoni tal-viremija kkawżata mill-virus tal-bluetongue, is-serotipi 1 u 8. il-bidu tal-immunità: 21 jum wara t-tlestija tal-iskema ta 'tilqim primarju. tul ta 'żmien tal-immunità: 12-il xahar.

Европска Унија - Мелтешки - EMA (European Medicines Agency)

ceva-phylaxia oltóanyagtermelõ zrt. - Ċirovirus tal-majjali inattiv ta 'tip 2 (pcv2) - immunoloġiċi għal suidae - majjali (ħnieżer nisa u majjali nisa) - Ħnieżer nisa u l-giltspassive-immunizzazzjoni tal-qżieqeż permezz tal-kolostrum, wara t-tilqim attiv tal-ħnieżer nisa żgħar u majjaliet, biex jonqsu l-feriti fit-tessuti tal-limf assoċjati ma ' infezzjoni b'pcv2 u bħala għajnuna biex jonqsu l-pcv2 marbuta mal-mortalità. pigletsactive-immunizzazzjoni tal-qżieqeż biex jonqsu l-ippurgar u l-eskrezzjoni tal-pcv2 u l-ammont ta 'virus fid-demm, u bħala għajnuna biex jonqsu l-pcv2 marbuta mal-sinjali kliniċi, inklużi l-ħela, telf fil-piż u l-mortalità, kif ukoll biex inaqqsu l-ammont ta' virus u leżjonijiet f'tessuti limfojde assoċjati ma ' infezzjoni b'pcv2.

Европска Унија - Мелтешки - EMA (European Medicines Agency)

mcm vaccine b.v. - toxoid tad-difterite, toxoid tat-tetnu, bordetella-antiġeni tal-pertussis: toxoid tal-pertussis, filamentużi haemagglutinin, pertactin, fimbriae tipi 2 u 3, l-epatite b-antiġen tal-wiċċ prodott f'ċelloli tal-ħmira, poliovirus (inattivat): tat-tip 1 (mahoney), it-tip 2 (mef-1), it-tip 3 (saukett) prodott f'ċelloli vero/ haemophilus influenzae tat-tip b polysaccharide (polyribosylribitol phosphate) konjugat meningokokkali-proteina. - meningitis, haemophilus; poliomyelitis; tetanus; diphtheria; whooping cough; hepatitis b - vaċċini - vaxelis (dtap-hb-ipv-hib) huwa indikat għall-vaċċinazzjoni primarja u booster fit-trabi u toddlers mill-età ta ' 6 ġimgħat, kontra diphtheria, tetanus, pertussis, epatite b, poliomyelitis u invażivi mard ikkawżat minn influwenza Ħemofillika tip b (hib). l-użu ta 'vaxelis għandu jkun skond ir-rakkomandazzjonijiet uffiċjali.

Европска Унија - Мелтешки - EMA (European Medicines Agency)

glaxo group ltd. - amprenavir - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - agenerase, flimkien ma 'mediċini antiretrovirali oħra, huwa indikat għall-kura ta' impeditur protease (pi) b'esperjenza ta 'adulti infettati bl-hiv-1 u tfal' l fuq minn 4 snin. il-kapsuli ta 'agenerase għandhom normalment jiġu amministrati b'doża baxxa ta' ritonavir bħala stimulant farmakokinetiku ta 'amprenavir (ara sezzjonijiet 4. 2 u 4. l-għażla ta 'amprenavir għandha tkun ibbażata fuq ittestjar ta' reżistenza virali individwali u l-istorja tal-kura tal-pazjenti (ara sezzjoni 5. il-benefiċċju ta 'agenerase ma' ritonavir ma ntwerewx f'pi nave-pazjenti (ara sezzjoni 5.

Европска Унија - Мелтешки - EMA (European Medicines Agency)

novartis europharm ltd - valsartan, amlodipine (as amlodipine besilate) - pressjoni għolja - aġenti li jaġixxu fuq is-sistema renin-angiotensin - trattament ta 'ipertensjoni essenzjali. imprida huwa indikat f'pazjenti li l-pressjoni tad-demm mhijiex ikkontrollata adegwatament bl-amlodipina jew valsartan monoterapija.

Европска Унија - Мелтешки - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - diphtheria toxoid, hepatitis b surface antigen, bordetella pertussis (inactivated), tetanus toxoid - hepatitis b; tetanus; immunization; whooping cough; diphtheria - vaċċini - tritanrix hepb huwa indikat għal immunizzazzjoni attiva kontra d-difterite, it-tetnu, it-pertussis u l-epatite b (hbv) fit-trabi minn sitt ġimgħat 'il quddiem (ara sezzjoni 4.

Европска Унија - Мелтешки - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - majjali - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.